Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

No results yet

Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE

The pivotal phase 3 EPITOPE trial, a 12-month, double-blind, placebo-controlled study of epicutaneous immunotherapy with the VIASKIN patch containing 250 μg of peanut protein (VP250), previously reported significant treatment response versus placebo in peanut-allergic toddlers aged 1 through 3 years.

Citation:
Greenhawt M, Albright D, Anvari S, …….. O’Sullivan M, Parrish C, et al. Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE. J Allergy Clin Immunol Pract. 2025;13(5):1176-87.e7. 

Keywords:
Anaphylaxis; Desensitization; Epicutaneous immunotherapy; Open-label study; Peanut allergy; Pediatrics; VIASKIN patch

Abstract:
The pivotal phase 3 EPITOPE trial, a 12-month, double-blind, placebo-controlled study of epicutaneous immunotherapy with the VIASKIN patch containing 250 μg of peanut protein (VP250), previously reported significant treatment response versus placebo in peanut-allergic toddlers aged 1 through 3 years.